General Information Email: ohsufinfo@ohsu.edu, Mailing Address shivaani kummar ohsu email. Patients and Methods. Web Browser Accessibility, Oncology experts will head the Division of Hematology and Medical Oncology, direct new center for experimental therapeutics, Shivaani Kummar, M.D., and her husband Sanjay Malhotra, Ph.D., will co-lead the Knight Cancer institutes new Center for Experimental Therapeutics, uniting cutting-edge technologies with multidisciplinary preclinical and clinical investigators. In addition to her role as division head, Kummar will serve as co-director for a new center in the Knight Cancer Institute, theCenter for Experimental Therapeutics, which she will co-lead with Sanjay Malhotra, Ph.D. Kummar brings a wealth of experience in conducting clinical trials tailored to make early, informed decisions regarding the suitability of new drug candidates for further clinical investigation. The new unit centralizes care for patients in research studies and expands capacity to allow more people to participate in early-phase clinical trials at OHSU. . Dr. Kummar joined the OHSU Knight Cancer Institute from Stanford University in July 2020. Shivaani Kummar (Principal Investigator, PI), OHSU Mary Crowley Cancer Research, Montefiore Medical Center 4 1 . Tom Sellers was named lead research officer at OHSU Knight Cancer Institute. . February 17, 2023 In Brief Edith Mitchell named enterprise vice president for cancer disparities at Jefferson SKCC When were developing new treatments for cancer, we are often trying to identify what makes the cancer different from normal cells or why currently used drugs are not working as well as we would like them to. Within our Center for Experimental Therapeutics, Knight Cancer Institute, we have multiple ongoing projects trying to identify new ways to target cancer. Lisa M. Coussens, M.D. Our new center will foster collaboration across disciplines, bringing together investigators interested in developing new treatments, Malhotra says. Kummar and Malhotra who have a high school-aged daughter and middle school-aged son met while she was faculty at Yale University. Shivaani Kummar Director of Center for Experimental Therapeutics, Professor and Endowed Chair, Knight Cancer Institute OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Members receive periodic email communication about events, programming, news and funding opportunities. Local: (503) 228-1730 | Toll Free: (800) 462-6608 Our patients in research studies can come in for their initial blood work and continue through their post treatment observation all in one place and are surrounded by a team of experts guiding them through the process.. 23 () 'Oregon Health & Science University Knight Cancer Institute (OHSU)' BAL0891 1 . A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, Clinical cancer research 18 (8), 2344-2351. Email: trials@ohsu.edu Call: 503-494-1080 Oregon Health & Science University. Shivaani Kummar. Due to Covid-19 pandemic, the 2020 Symposium was postponed to 2021. 2001-2023 OHSU. Sign up to receive the latest news, updates and stories from the OHSU Foundation in your inbox. Increasing patient participation in oncology clinical trials, A Novel Artificial IntelligencePowered Method for Prediction of Early Recurrence of Prostate Cancer after Prostatectomy and Cancer Drivers, Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas, Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer. She received her medical degree from Lady Hardinge Medical College and has been in practice for . Web Browser Accessibility, New early-phase clinical trial unit in the Center for Health and Healing Building 2 on South Waterfront centralizes care for cancer patients, provides more research opportunities, OHSU expands capacity for cancer clinical trials, OHSU Knight Cancer Institute: Understanding Cancer Clinical Trials, Expanding access to experimental cancer treatments in Oregon: Q&A with Shivaani Kummar, Severe respiratory illness season means boom times for OHSU virtual immediate care, OHSU leading effort to make cancer trials more inclusive, OHSU Child Life Specialist provides life-changing care to young patient living with chronic spinal condition, Making Hepatitis C care easier when treatment seems impossible. Across OHSU, doctors and researchers are reimagining early disease detection. What is the importance of philanthropy to your work? These new agents include those targeting genetic changes (alterations in the DNA of the cancer cell), those that harness the immune system to work against the cancer, and others. We are proud to be able to offer our patients access to the most advanced cancer therapies available, said Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institutes Center for Experimental Therapeutics. DS Hong, SG DuBois, S Kummar, AF Farago, CM Albert, KS Rohrberg, S Kummar, R Kinders, ME Gutierrez, L Rubinstein, RE Parchment, Journal of clinical oncology 27 (16), 2705. Sanjay Malhotra, Ph.D. Shivaani Kummar, M.D., FACP You may also qualify for Phase 1 Program trials. Cancer and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Blood Diseases, Cancer and Blood Disorders, Hematology and Oncology, Cancer, Cancer and Blood Disorders and Benign Blood Disorders, Cancer, Hematology Oncology and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Medical Oncology and Hematology, Cancer, Blood Diseases and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Bladder Cancer, Cancer, Hematology Oncology and Blood Cancers, Hospice and Palliative Care, Internal Medicine and Psychiatry, Hospice and Palliative Care and Palliative Care, Hospice and Palliative Care, Internal Medicine and Geriatrics, Sarah Lowry, D.N.P., ACNP-BC, AOCNP, ACHPN, Thomas G. DeLoughery, M.D., M.A.C.P., FAWM. what was bolivar's ultimate goal? She shares our urgency to better understand how research and drug development can help the patients who desperately need better treatments, today.. With this new dedicated space to administer clinical trial care for patients, OHSU will continue to work to expand access to innovative clinical trials for cancer patients in Oregon and beyond.. Administrative Coordinator, Felicia Feingersch Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, New England Journal of Medicine 378 (8), 731-739. Palliative Care Administrative Assistant. Bergan, R., Coussens, L., McWeeney, S., Spellman, P., Streeter, P., Winters-Stone, K., Bagby, G., Mori, M., Corless, C., Harrington, C., Hoatlin, M., Koop, D., Magun, B., Druker, B., Shannon, J. This new unit allows us to centralize everything in a setting designed for a patients convenience and comfort, said Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute. Share on email. Dr. Shivaani Kummar is an oncologist in Palo Alto, California and is affiliated with OHSU Hospital. Over the past six months, a multidisciplinary team has been coordinating patient experience, drug delivery, staffing schedules and equipment needed to support the range of clinical trials offered in the unit that span 14 different cancer disease groups. OHSU Foundation P.O. Learn more about clinical trials at the Knight Cancer Institute, The 13,000-square-foot early-phase research unit includes 12 treatment spaces, eight chairs, four beds, and procedure and consultation rooms. Cited by. Web Browser Accessibility, A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF MECBOTAMAB VEDOTIN (BA3011) ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH ADVANCED SOLID TUMORS, A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor, A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination with Anticancer Therapies in Subjects with Solid Malignancies, A double-blind, placebo-controlled, randomized, dose-escalating, multicenter, Phase 1 study to assess the safety and tolerability of ART-123 in combination with leucovorin/5-fluorouracil/oxaliplatin and bevacizumab in metastatic colorectal cancer patients, A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients with Advanced Solid Malignancies, A PHASE 1 STUDY OF KSQ-4279 ALONE AND IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS. Shivaani Kummar. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. We are asking this question from time to time, and we expect to uncover a globe-full of roads to Stanford. Notice of Privacy Practices OHSU HOSPITAL AND CLINICS - (Acute Care) 3181 SW SAM JACKSON PARK ROAD Very few institutions do it well, but OHSU truly gets it, Kummar says. The unit includes 12 treatment spaces, eight chairs, four beds, and procedure and consultation rooms. OHSU is an equal opportunity affirmative action institution. NPI Lookup NPI Database. As an oncologist, Dr. Kummar manages and oversees the treatment of a cancer patient after he or she has been diagnosed with the disease. A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. The OHSU Knight Cancer Institute is part of regional, national and international research partnerships, offering patients local access to the latest advances and clinical trials. Hamburger Menu x Home Keep me signed in. Their mission is clear: To give patients excellent care. She co-leads a team of 90 faculty members and along with her husband, Sanjay Malhotra, PhD, is focused on discovering new therapies for cancer and giving more people access to safe, experimental cancer treatments. By using this website, we will assume that you agree to the terms and conditions of our privacy policy. If you proceed in scheduling an appointment and your healthinsurancebenefits do not participate with OHSU providers, your out of pocket liability may be higher. Abstracts & Presentations. Username or E-mail. We are delighted she has chosen to join us, said Brian Druker, M.D., director of the OHSU Knight Cancer Institute. The provider's speciality is Internal Medicine with a focus in Medical Oncology How many years of experience does Dr. Shivaani Kummar have? Web Browser Accessibility, An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) as monotherapy or combination therapy in subjects with advanced cancer. & Kummar, S. Research output: Contribution to journal Comment/debate peer-review, Research output: Contribution to journal Review article peer-review, Research output: Contribution to journal Article peer-review, Powered by Pure, Scopus & Elsevier Fingerprint Engine 2023 Elsevier B.V, We use cookies to help provide and enhance our service and tailor content.
Jp Morgan Corporate Analyst Development Program Intern Salary,
Little Jack Horner Cold House,
Articles S
